Page last updated: 2024-11-08

triiodothyronine and Carcinoma in Situ

triiodothyronine has been researched along with Carcinoma in Situ in 1 studies

Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.

Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Meirovitz, A1
Nisman, B1
Allweis, TM1
Carmon, E1
Kadouri, L1
Maly, B1
Maimon, O1
Peretz, T1

Other Studies

1 other study available for triiodothyronine and Carcinoma in Situ

ArticleYear
Thyroid Hormones and Morphological Features of Primary Breast Cancer.
    Anticancer research, 2022, Volume: 42, Issue:1

    Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Carcinoma in Situ; Cell Proliferation; Female; Hum

2022